News & Updates

Starting alirocumab early in the hospital prior to undergoing percutaneous coronary intervention (PCI) reduces LDL-cholesterol (LDL-C) in STEMI* patients already on high-statin therapy.

A novel thrombectomy device using a sequestered approach delivers positive clinical outcomes in the treatment of high-risk, large-volume deep vein thrombosis (DVT), according to a study.

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In patients with multivessel coronary artery disease, the risk of any-cause death, myocardial infarction (MI), or target vessel revascularization (TVR) did not vary according to whether patients underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES) or coronary artery bypass graft (CABG), extended follow-up of the BEST* trial showed.

Cuff-based estimates of systolic blood pressure (SBP) amplification demonstrate proportional systematic bias and less individual variability regardless of the difference from invasive measurements, according to a recent study.

Individuals with depressive symptoms are more susceptible to cold-induced increase in their blood pressure (BP) compared to nondepressive counterparts, suggests a Japan study.